<DOC>
	<DOC>NCT01759264</DOC>
	<brief_summary>The objective of this observational study was to assess changes in fecal calprotectin levels and its suitability as a monitoring tool in participants with moderate-to-severe Crohn's Disease who were treated with adalimumab.</brief_summary>
	<brief_title>An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. Crohn's Disease participants were defined as: 1. Active luminal, moderatetosevere Crohn's Disease with Crohn's disease activity index (CDAI) greater than 220, who started Adalimumab treatment in a normal clinical practice setting. 2. Fecal Calprotectin greater than or equal to 150 microgram/g. 3. Ileocolonic or colonic disease, with or without involvement of proximal gastrointestinal areas. 1. Disease restricted to proximal (small bowel, gastroduodenal) gastrointestinal tract. 2. Participants who had undergone colectomy other than ileocecal resection. 3. Pregnancy or breast feeding. 4. Contraindication to any antitumor necrosis factors (TNF) agent. 5. Any drug dependency.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Fecal Calprotectin</keyword>
	<keyword>Crohn's Disease</keyword>
	<keyword>Adalimumab</keyword>
</DOC>